28 September 2026
Latham & Watkins Advises on ADARx Pharmaceuticals’ Upsized US$446.3 Million Initial Public Offering
Advising firms
Deal team
17 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Matt Bush Lead | Latham & Watkins LLP | Partner | Capital Markets | San Diego |
| Anthony Gostanian | Latham & Watkins LLP | Counsel | Not stated | Not stated |
| Julian Brody | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Sterling Swift | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Zach Kobayashi | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Chad Jennings | Latham & Watkins LLP | Counsel | FDA matters | Washington, D.C. |
| Trevor Thompson | Latham & Watkins LLP | Associate | FDA matters | Not stated |
| Betty Pang | Latham & Watkins LLP | Partner | healthcare matters | Bay Area |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy and cybersecurity matters | Bay Area |
| Chad Leiper | Latham & Watkins LLP | Associate | data privacy and cybersecurity matters | Not stated |
| Robert Yeh | Latham & Watkins LLP | Counsel | intellectual property matters | San Diego |
| Patrick Chew | Latham & Watkins LLP | Associate | intellectual property matters | Not stated |
| Holly Bauer | Latham & Watkins LLP | Partner | executive compensation and employee benefits matters | San Diego |
| Sara Schlau | Latham & Watkins LLP | Associate | executive compensation and employee benefits matters | Not stated |
| Julie Voorhes | Latham & Watkins LLP | Associate | executive compensation and employee benefits matters | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax matters | Los Angeles |
| Jay Khurana | Latham & Watkins LLP | Associate | tax matters | Not stated |
14 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 446m (US$446.3 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- AbbVie (Investor)